Navigation Links
Osteotech Reports First Quarter 2009 Financial Results
Date:4/30/2009

1, 2009 was $1.8 million, or $0.10 per diluted share, compared with net income of $808,000, or $0.05 per diluted share, for the first quarter of 2008.

"Looking ahead, we are well positioned to launch or unveil MagniFuse, Plexur M, DuraTech and Facetlinx(TM) Facet Fusion Graft, our procedure-specific spine product, and we believe we are taking the steps necessary, particularly within our sales distribution network, to encourage demand," continued Mr. Owusu-Akyaw. "Based upon the investments we have made in our business and the emerging trends in orthopedics, we believe we are well positioned to emerge as a leader in the industry. We believe our proprietary technology platforms and research and development capabilities provide us with a technology lead that will be difficult to penetrate. We remain focused on increasing shareholder value and believe that the potential for sustainable, profitable revenue growth will allow us to reach our goal of providing significant returns to all of our stakeholders."

Guidance

Based upon the results achieved to date, Osteotech is reiterating the financial guidance it has previously established for 2009:

  • Overall revenue is expected to range between $96 million and $100 million;
  • Net loss for 2009 is expected to be between $0.05 and $0.07 per share; the Company remains on track to generate free cash flow from operations in 2009; and
  • The Company expects to exit 2009 with approximately $15 million in cash.

Conference Call Tomorrow, May 1, 2009

The Osteotech management team will host a conference call on May 1, 2009 at 9:00 a.m. (EDT) to discuss first quarter 2009 financial results, recent corporate developments and guidance for 2009. The conference call may be accessed by dialing 1-866-783-2141 (domestic) or 1-857-350-1600 (international) and indica
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
5. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
6. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
7. Osteotech to Present at the Sidoti Conference in New York
8. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
9. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
10. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
11. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asian ... in Asian with analysis and forecast of revenue. The ... grow to around $463.9 million by 2018, at a ... Browse through the TOC of the Asian Automatic patient ... analysis provided. This also provides a glimpse of the ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems report ... and forecast of revenue. The Orthopedic braces and support systems ... million by 2018, at a developing CAGR of 4.4% from ... Asian Orthopedic braces and support systems market, to get an ... glimpse of the segmentation of orthopedic braces and support systems ...
(Date:10/18/2014)... 2014 The “Human Insulin Market- ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:10/18/2014)... The Asian arthroscopic devices report defines ... and forecast of revenue. The arthroscopic devices market in ... 2018, at a CAGR of 6.5% from 2013 to ... arthroscopic devices market, to get an idea of the ... the segmentation of arthroscopic devices market in the same ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4
... - - ... -, SOUTH SAN FRANCISCO, Calif., Aug. 17 ... U.S. Food and Drug,Administration (FDA) has approved Zingo(TM) (lidocaine ... analgesia to reduce the pain associated with venous access,procedures, ...
... (Nasdaq: IDEV ) today announced that it ... and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a sterile ... product approved by the FDA for therapy of,bacillus ... bladder. VALSTAR was removed from the market ...
... Union announced today they,have entered into a five-year ... in Region 3 to provide RealTime1(TM) (RT1(TM)),software at ... and the,US Virgin Islands. The Region 3 Genetics ... funding for another five-year period.,With this renewal, Region ...
Cached Biology Technology:Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 2Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 3Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 4Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 5Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4Digital Union's RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative 2
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... genes can reveal not only the "lifestyle" of marine microbes ... finding means researchers may be able to predict the types ... the genomes of just a few dominant species, according to ... Wales. As well, it may reveal new insights into the ...
... removed during liposuction conceal versatile cells that are more ... cells, or iPS cells, than are the skin cells ... study from Stanford,s School of Medicine. "We,ve identified a ... of the research, Michael Longaker, MD, who has called ...
... for 50 percent of the fish consumed globally, according to ... while the industry is more efficient than ever, it is ... large amounts of feed made from wild fish harvested from ... the Sept. 7 online edition of the Proceedings of ...
Cached Biology News:Genomes reveal bacterial lifestyles: Research 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 2'Liposuction leftovers' easily converted to IPS cells, Stanford study shows 3Half of the fish consumed globally is now raised on farms, study finds 2Half of the fish consumed globally is now raised on farms, study finds 3
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Sprague Dawley rats, 7-8 weeks of age, mixed gender; collected by exsanguination in Alsever's solution at 1:2 dilution...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... BAC (100+kb), fosmid (40kb), and large plasmid ... any othe BAC vector. On command 20-50 ... easy recombinant DNA purification. Available with blue-white ... vectors for the highest insert stability. Kits ...
Biology Products: